[A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996].
The objective was to assess the cost-effectiveness ratio of HAART in the treatment of HIV infection. Two random samples were extracted from the database of the Rothschild Public Hospital, and patients were matched for age, sex and T4 cell counts: a first sample selected in 1996/97 of HAART treated patients (CAS group) and a second sample selected in 1994/95 of non-HAART treated patients (CONTROL group). Immune recovery and use of resources data were extracted and analyzed over two years for 196 included patients. Mean T4 cell count after two years was higher among CAS patients (344/mm3 vs. 234/mm3; p < 0.0001). CAS patients recorded a supplementary cost of antiretroviral treatments (+171%; p < 0.0001) balanced by savings in other drugs expenses (-62%; p = 0.0560) and in hospitalizations (-25%; NS). Overall, CAS patients presented a 15% (NS) lower medical cost than CONTROL patients.
Le Pen
C
C
Université de Paris Dauphine, France. claude.lepen@clp-sante.fr
Rozenbaum
W
W
Downs
A
A
Lilliu
H
H
Maurel
F
F
Foucher
F
F
D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000639:trends*; D003362:Cost-Benefit Analysis; D005602:France; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D013601:T-Lymphocytes / Q000187:drug effects
D019380:Anti-HIV Agents